ACHIEVED PRIMARY ENDPOINT OF STATISTICALLY SIGNIFICANT IMPROVEMENT IN MFARS COMPARED TO PLACEBO AFTER 48 WEEKS OF TREATMENT Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical...

Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system...

This is a review article focusing on the insights into the pathogenesis of this disorder and how those insights are being translated into novel therapeutic...

The aim of the present study was to characterize and analyze the most important individual and organizational variables associated with job accommodation in subjects with...